Psy112 - Factor Utilization Analysis of Extended Duration and Standard-Acting Recombinant Fviii Treatments for Severe Hemophilia a in Sweden
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2687
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV